drugset / Trial / NCT00733980
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
Timeline
- Start
- 2008-10-02
- Primary completion
- 2010-06-18
- Completion
- 2010-06-18
Outcome
Missed primary endpoint
registry analysis (superiority or other test); GSK561679 vs Placebo; p = 0.703; Mean Difference (Net) 0.2479 (80% CI -0.5887 to 1.0846); Mixed-Model Repeated-Measure analysis NCT00733980 ↗
release “no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints” gcs-web.com ↗
Publications
- Background GSK has concluded that it is not feasible to publish this study in a peer-reviewed scientific journal because the nature of the study is unlikely to be of interest to a journal. GSK is providing the attached study results summary with a conclusion.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VERUCERFONT | Small molecule | 350 mg | — |